Machine learning and tear-fluid proteomics identify a six-protein ALS signature
In discovery samples from 49 people with amyotrophic lateral sclerosis (ALS) and 54 controls, mass spectrometry detected 876 tear-fluid proteins, of which 106 differed in abundance. Biostatistical and machine-learning analyses produced a six-protein signature (CRYM, PFKL, CAPZA2, ALDH16A1, SERPINC1 and HP). In an independent cohort of 51 ALS cases and 52 controls, Western blots replicated significant group differences for SERPINC1 and HP; their combination had the best reported in-silico discrimination.
Technology: Machine-learning models applied to data-independent acquisition mass-spectrometry proteomics and biomarker-panel discrimination
Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: direct test
- Tested: In an independent cohort of 51 ALS cases and 52 controls, Western blots replicated significant group differences for SERPINC1 and HP; their combination had the best reported in-silico discrimination.
- Still unknown: This is an exploratory biomarker study with modest discovery and validation cohorts, not a clinically validated diagnostic assay. The article reports that only SERPINC1 and HP differences replicated significantly across cohorts; the six-protein signature is a candidate and its best discriminatory performance was evaluated in silico. It does not establish ALS-specific causality or clinical utility.
- AI role: Machine learning contributed to identification of ALS-associated differential proteins and pathways and evaluated discrimination by the derived signature. The selected tear-fluid proteins were then assayed in an independent patient/control cohort by Western blot; only SERPINC1 and HP differences are explicitly reported as replicated across cohorts.
Evidence sources: https://actaneurocomms.biomedcentral.com/articles/10.1186/s40478-025-02109-6
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: linked separately.
Review scope and date are not recorded; source checked does not establish full-text review.
Citations: in the top 10% of works of the same type, year and subfield (OpenAlex work metrics, 6 citations; as of 15 Nov 2026). Attention, not a measure of correctness; not part of the score.
Editorial assessment: Impact 2/5 · Validation 3/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.